European drug regulators have given the marketing green light to Invokana (canagliflozin), a new type of type 2 diabetes medication. The drug was approved by the U.S. Food and Drug Administration (FDA) in May and was the first in the U.S. and the second in Europe from a new class of medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors are designed to help reduce blood sugar levels by preventing the reabsorption of glucose from the kidneys back into the blood so that more glucose is excreted in the urine. Invokana is a once-daily treatment for adults with type ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.